Cervical cancer vaccine gives long protection

	Tweet

A vaccine that protects women against a virus that causes cervical cancer is effective for more than four years, researchers said on Thursday.

They found that women given GlaxoSmithKline Plc’s cervical cancer vaccine Cervarix had high levels of antibodies against two of types of the human papillomavirus (HPV) for up to 4.5 years after receiving their last dose.

“These findings set the stage for widescale adoption of HPV vaccination for prevention of cervical cancer,” said Dr Diane Harper, of Dartmouth Medical School in New Hampshire, who conducted the trial.

Cervical is one of the most common cancers in women. Each year 470,000 women around the world are diagnosed with the disease and 230,000, mostly in the developing world, die, according to the International Agency for Research on Cancer (IARC) in Lyon, France.

HPV is a sexually transmitted infection. Strains 16 and 18 of the virus are responsible for more than 70 percent of cervical cancers.

Results of a European survey released on Wednesday of more than 1,500 women in five EU countries showed that only 5 percent could identify HPV as the cause of cervical cancer.

Harper and her team followed up 800 women who took part in the original trial of the vaccine in which it was compared to a placebo. Their research is published online by The Lancet medical journal.

Women given the vaccine not only had high levels of antibodies against HPV-16 and HPV-18 but the levels did not decrease over time.

The vaccine also protected against new and persistent infections and was effective against HPV-45 and HPV-31, the third and fourth most prevalent cancer-causing types of the virus.

“The results show sustained immune response and long-term efficacy against HPV-16 and HPV-18 infection,” Harper added.

Glaxo submitted the vaccine to the European Medicines Agency for approval in March. But Merck & Co. Inc’s Gardasil vaccine was filed for marketing approval in Europe and the United States last December.

Merck is marketing the vaccine in partnership with Sanofi-Aventis in Europe. 

RELATED STORIES:
Health groups issue proposed cervical cancer screening guidelines   Cervical cancer screening rates low in poor areas   Singapore questions cervical cancer vaccine for teens   Scientists identify how virus triggers cervical and mouth cancer   Cervical Cancer Rates Higher Among Minority Women   High cervical cancer rates sign of larger problems   Staging of cervical cancer complicating pregnancy   Newer cervical cancer test no better than the old?   UK mothers back cervical cancer vaccine for kids   Merck cervical cancer shot gives 5-year protection   Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia   Smoking increases risk cervical cancer   Higher rates of cervical cancer amongst immigrants   Cervical cancer drops, but disparities persist   Newly Created Cancer Stem Cells Could Aid Breast Cancer Research   Merck’s cervical cancer vaccine on sale in Europe   Adding test for cervical cancer raises costs: study   Teen Vaccinations against Cervical Cancer Lagging   Good results with cervical cancer vaccine in young girls   High HPV Concentrations, Smoking Significantly Raise Risks of Cancer   Gates backs cervical cancer vaccines for poor   Vaccines alliance nears deal on cervical cancer shots

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]